JULY 23, 2024 HIV infecting a human cell. Credit: NIHA new “vaccine-like” HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated on Tuesday. The antiretroviral drug Lenacapavir, developed by US pharmaceutical giant Gilead, has been hailed as a potential game-changer in the fight...
MAY 30, 2024 Microscopic image of an HIV-infected T cell. Credit: NIAID More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly...
by Boston University Credit: Unsplash/CC0 Public Domain In 2019, the World Health Organization formally recommended the drug dolutegravir (DTG) as the preferred antiretroviral therapy (ART) for people living with HIV in low and middle-income countries (LMICs), citing that it is more effective and tolerable, less costly, and less prone to developing drug resistance than the previously recommended...
MASSACHUSETTS GENERAL HOSPITAL BOSTON — New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer. Findings from the trial, published in Cancer Discovery, raise the possibility of an unexpected promising direction in cancer treatment, not just colorectal cancer. The trial included...
New results presented at HIVR4P finds no dapivirine-associated resistance detected among women who acquired HIV while using dapivirine vaginal ring in ASPIRE MICROBICIDE TRIALS NETWORK MADRID, October 24, 2018 – A monthly vaginal ring that slowly releases an antiretroviral (ARV) drug called dapivirine is currently undergoing regulatory review. If approved, the dapivirine ring would be the first biomedical HIV prevention method developed...
Gilead is looking to bictegravir to defend its HIV franchise against GSK Gilead has posted upbeat phase 2 data on its next-generation integrase inhibitor bictegravir in HIV patients. The drug more than held its own against GlaxoSmithKline’s dolutegravir, setting the stage for a larger-scale comparison in phase 3 and potential scrap for a multibillion-dollar market. The trial...
